Wyeth To Revisit Launch Plans For Effexor XR Follow-On
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.
You may also be interested in...
Wyeth Anticipates “Approvable” Letter For Effexor XR Follow-On
CEO Essner says issues at firm’s Puerto Rico manufacturing facility are one reason to expect an approvable letter.
Wyeth Anticipates “Approvable” Letter For Effexor XR Follow-On
CEO Essner says issues at firm’s Puerto Rico manufacturing facility are one reason to expect an approvable letter.
Effexor XR Labeling Update Advises Of Increased Risk Of Fatal Outcomes Versus SSRIs
Wyeth issues “Dear Healthcare Provider” letter advising that venlafaxine overdose may be associated with increased risk of fatal outcomes.